Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DURABLE trial of durvalumab monotherapy in unresectable hepatocellular carcinoma with Child-Pugh B
jRCTs041250091Phase 2Recruiting
- Sponsor
- Japan Oncology Network in Hepatobiliary and Pancreas
- Start
- Feb 2026
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in hepatocellular carcinoma (HCC), sponsored by Japan Oncology Network in Hepatobiliary and Pancreas. Primary endpoint: Frequency of treatment-related severe adverse events within 6 months. Started Feb 2026; status: recruiting.
02
Drugs
durvalumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCTs041250091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041250091.